Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant advancements in its lead product, tegoprubart. The company reported a net loss of $45.6 million for the year, which reflects a slight increase from the previous year's loss of $36.2 million. Notably, the 2025 results included a non-cash gain of $33.4 million from changes in the fair value of warrant liabilities, indicating a strong financial position despite the losses. Eledon has made substantial progress in its clinical development programs, particularly in the area of transplantation. The company reported updated results from a study involving 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation, achieving 100% insulin independence in patients more than four weeks post-transplant. The favorable safety and tolerability profile of tegoprubart was further supported by 24-month follow-up data from a Phase 1b long-term extension study. Additionally, the FDA granted Orphan Drug designation for tegoprubart for the prevention of allograft rejection in liver transplantation, which is expected to enhance its market potential. Looking ahead, Eledon anticipates multiple milestones in 2026, including regulatory engagement to support advancement into Phase 3 development in kidney transplantation and the initiation of additional clinical trials. The company remains committed to addressing key safety and efficacy issues in transplant immunosuppression, positioning itself as a leader in this critical therapeutic area.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.